ABSTRACT
The outbreak of a new coronavirus disease (COVID-19), caused by SARS-CoV-2, appears to be the greatest medical challenge of the last decade. In adult patients, COVID-19 affects the lungs in particular, manifesting in the form of interstitial pneumonitis (NSIP) and acute respiratory distress syndrome (ARDS). According to available data, COVID-19 in children is less common and has a milder course, often in the form of asymptomatic carriage or with digestive problems only. It is very likely that the occurrence of the infection caused by SARS-CoV-2 in this age group is underestimated. Currently, it is estimated to range from 0.9 to 12 percent in the paediatric population. The latest data on new mutations of the virus suggest its new "peculiarities”. It has turned out that the SARS-CoV-2 virus is becoming more infectious, from the summer months there has been a growing incidence of the disease in children and, moreover, there are more and more cases when it causes damage to various organs, including the brain. Temporal association with the COVID-19 infection reveals new units: paediatric multisystem inflammatory system temporally associated with SARS-CoV-2 (PIMS-TS / MIS-C / Kawa-COVID-19) – a systemic inflammatory disease of unknown etiology, similar to the Kawasaki disease or the Kawasaki shock syndrome, with sudden onset of cardiogenic and circulatory shock. Symptoms of Kawa-COVID-19 occur in paediatric patients approximately 2 – 4 weeks after recovery from SARS-CoV-2 and the most common complication occurring in 50% cases is myocarditis. Development of vasculitis may also lead to aneurysms and other cardiovascular complications. Much depends on the stage of the disease in which the child is admitted to the hospital, as well as on how fast the treatment is initiated. The objective of this article is to draw the attention of the expert public to the previously mentioned risks and to prevent potential cardiovascular complications © 2022, Lekarsky Obzor.All Rights Reserved.
ABSTRACT
Background: At present, during the coronavirus disease (COVID-19) pandemic, chronic pain is becoming more prominent, and it is also associated with the post-COVID-19 syndrome. Thanks to quick decisions on the therapy and as part of COVID-19 prevention, we have succeeded in stabilising the situation all over the world. On the other hand, 'quick decisions' have contributed to other significant issues which we are beginning to deal with now: in the effort to defeat the virus, many experts regarded the adverse effects of the medications used to be of secondary importance. Purpose: The article aims to demonstrate the side effects of treatment with various drugs (and their combinations) that are used to treat COVID-19 disease. Method: From the beginning of January until mid-May, the COVID-19 department of the 2nd Surgical Clinic of the Faculty of Medicine of the Comenius University in Bratislava (University Hospital Bratislava, Hospital of Saints Cyril and Methodius) treated 221 patients with moderate and severe course of COVID-19 (2nd wave of the pandemic). We saw some adverse effects and lack of effect of certain drugs for COVID-19. Results: The benefits of preventive measures compared to treatment are enormous. For example, corticoids can impair metabolism, cause diabetes, or suppress immunity. Antibiotics may cause colitis and blood pressure medications may negatively impact blood circulation. Conclusion: Preventive measures such as vaccination and activation of intrinsic antiviral immune systems are based on an incomparable benefit. Important in the process of the activation of antiviral immunity (linked to interferon synthesis) in the prevention of COVID-19 is the improvement of vitamin D deficit and the use of other micronutrients. Practical value: The results of the study will be valuable in the field of medicine, for virologists, pharmacologists, pharmacists, and medical professionals.
ABSTRACT
The COVID-19 pandemic has affected the lives and health of people all around the world. Although majority of patients with COVID-19 experience respiratory symptoms, pain is also a very important symptom. The condition of 15-20% of patients is serious and requires hospitalization. Despite the fact that the disease was initially referred to as a respiratory disease, it often affects other systems as well;the most common are the cardiovascular, urologic and nervous system. Multi-organ involvement increases the need for intensive care and treatment of several consequences caused by the disease. Due to severity of the disease, the management of complications following release from hospital should also be considered. The provision of multidisciplinary care that supports both physical and mental recovery in the initial stages of hospitalization can minimize the damage. Cognitive, physical and mental dysfunction reported by COVID-19 patients after discharge may have significant impact on the quality of human life. Pain is usually part of the dysfunction. The post-COVID-19 pain syndrome is still not completely understood, in particular the way it affects patients after they have recovered from COVID-19. There is limited information on the clinical characteristics, treatment, results and pain management in COVID-19 patients. The aim of our article is to provide an overview of the impact COVID-19 has on conditions associated with acute and chronic pain.
ABSTRACT
Background: An interesting clinical case of viral pneumonia in a 16-year-old patient is considered in the article. This case deserves attention of anesthesiologists, especially today, during the COVID-19 epidemic. An important role in timely diagnosis belongs to the CT scan, as the X-ray does not always diagnose viral pneumonia. In our case, we adhered to the principles of restrictive infusion therapy, early intubation, protective ventilation and early weaning of the patient from the respirator. The article describes the successful experience of using the ASV intelligent ventilation mode – from intubation to extubation. Were commend you to use ASV in patients with viral pneumonia to achieve protective ventilation, rapid weaning, and low risk of complications. © 2021